Background：Diabetes mellitus （DM） remains a major health problem worldwide.Several clinical trials have shown the superiority of the Traditional Chinese Medicine in delaying or reversing the development and progres...Background：Diabetes mellitus （DM） remains a major health problem worldwide.Several clinical trials have shown the superiority of the Traditional Chinese Medicine in delaying or reversing the development and progression of DM.This study aimed to evaluate the efficacy of Jinlida （JLD） granule,a Chinese herbal recipe,in the treatment of impaired glucose tolerance （IGT） and its effect on the prevention of DM.Methods：Sixty-five IGT patients were randomized to receive one bag of JLD granules three times daily （JLD group,n =34） or no drug intervention （control group,n =31） for 12 weeks.Oral glucose tolerance test,glycated hemoglobin A1c （HbA1c）,body mass index,blood lipids levels,fasting insulin,and insulin resistance calculated using homeostatic model assessment （HOMA-IR） of all the patients were observed and compared before and after the treatment.Results：Sixty-one participants completed the trial （32 in JLD group and 29 in the control group）.There were statistically significant decreases in HbA1c （P 〈 0.001）,2-h plasma glucose （P 〈 0.001）,and HOMA-IR （P =0.029） in JLD group compared with the control group after 12 weeks of treatment.After 12 weeks of treatment,two （6.9%） patients returned to normal blood glucose,and five （17.2%） patients turned into DM in control group,while in the JLD group,14 （43.8%） returned to normal blood glucose and 2 （6.2%） turned into DM.There was a significant difference in the number of subjects who had normal glucose at the end of the study between two groups （P =0.001）.Conclusions：JLD granule effectively improved glucose control,increased the conversion of IGT to normal glucose,and improved the insulin resistance in patients with IGT.This Chinese herbal medicine may have a clinical value for IGT.展开更多
文摘Background：Diabetes mellitus （DM） remains a major health problem worldwide.Several clinical trials have shown the superiority of the Traditional Chinese Medicine in delaying or reversing the development and progression of DM.This study aimed to evaluate the efficacy of Jinlida （JLD） granule,a Chinese herbal recipe,in the treatment of impaired glucose tolerance （IGT） and its effect on the prevention of DM.Methods：Sixty-five IGT patients were randomized to receive one bag of JLD granules three times daily （JLD group,n =34） or no drug intervention （control group,n =31） for 12 weeks.Oral glucose tolerance test,glycated hemoglobin A1c （HbA1c）,body mass index,blood lipids levels,fasting insulin,and insulin resistance calculated using homeostatic model assessment （HOMA-IR） of all the patients were observed and compared before and after the treatment.Results：Sixty-one participants completed the trial （32 in JLD group and 29 in the control group）.There were statistically significant decreases in HbA1c （P 〈 0.001）,2-h plasma glucose （P 〈 0.001）,and HOMA-IR （P =0.029） in JLD group compared with the control group after 12 weeks of treatment.After 12 weeks of treatment,two （6.9%） patients returned to normal blood glucose,and five （17.2%） patients turned into DM in control group,while in the JLD group,14 （43.8%） returned to normal blood glucose and 2 （6.2%） turned into DM.There was a significant difference in the number of subjects who had normal glucose at the end of the study between two groups （P =0.001）.Conclusions：JLD granule effectively improved glucose control,increased the conversion of IGT to normal glucose,and improved the insulin resistance in patients with IGT.This Chinese herbal medicine may have a clinical value for IGT.
文摘目的 探讨津力达颗粒联合地特胰岛素治疗妊娠期糖尿病(GDM)的临床效果,以期为临床治疗方式的选择提供参考。方法 将2018年1月至2020年12月我院收治的370例GDM患者根据治疗方法的不同分为联合组(186例,地特胰岛素+津力达颗粒)和对照组(184例,地特胰岛素)。比较两组的血管细胞粘附分子-1(VCAM-1)、晚期氧化蛋白产物(AOPP)、网膜素-1、血糖指标[空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(HbA1c)]、血脂指标[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平、预后不良事件发生情况及新生儿1 min Agpar评分。结果 治疗后,联合组的VCAM-1、AOPP、网膜素-1水平优于对照组(P<0.05)。治疗后,联合组的FBG、PBG水平及HbA1c低于对照组(P<0.05)。治疗后,联合组的TG、TC、LDL-C水平低于对照组,HDL-C水平高于对照组(P<0.05)。联合组的母体、新生儿预后不良事件总发生率低于对照组,新生儿1 min Agpar评分高于对照组(P<0.05)。结论 津力达颗粒、地特胰岛素可以协同降低GDM患者血糖、血脂水平,改善预后。
